| Anti–PD-L1 treatment induced central diabetes insipidus C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, ... The Journal of Clinical Endocrinology & Metabolism 103 (2), 365-369, 2018 | 104 | 2018 |
| FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice A Kommalapati, SH Tella, M Borad, M Javle, A Mahipal Cancers 13 (12), 2968, 2021 | 96 | 2021 |
| Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes A Kommalapati, SH Tella, M Durkin, RS Go, G Goyal Blood, The Journal of the American Society of Hematology 131 (2), 265-268, 2018 | 93 | 2018 |
| Second-line therapies in advanced biliary tract cancers SH Tella, A Kommalapati, MJ Borad, A Mahipal The Lancet Oncology 21 (1), e29-e41, 2020 | 92 | 2020 |
| Contemporary management of localized resectable pancreatic cancer A Kommalapati, SH Tella, G Goyal, WW Ma, A Mahipal Cancers 10 (1), 24, 2018 | 83 | 2018 |
| FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma A Mahipal, SH Tella, A Kommalapati, D Anaya, R Kim Cancer treatment reviews 78, 1-7, 2019 | 66 | 2019 |
| Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis SH Tella, A Kommalapati, R Correa Cureus 9 (5), 2017 | 59 | 2017 |
| Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database SH Tella, A Kommalapati, S Yaturu, E Kebebew The Journal of Clinical Endocrinology & Metabolism 103 (9), 3566-3573, 2018 | 56 | 2018 |
| Novel targeted treatment options for advanced cholangiocarcinoma A Mahipal, A Kommalapati, SH Tella, A Lim, R Kim Expert opinion on investigational drugs 27 (9), 709-720, 2018 | 51 | 2018 |
| Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma S Chakrabarti, SH Tella, A Kommalapati, BM Huffman, S Yadav, IB Riaz, ... Journal of gastrointestinal oncology 10 (3), 554, 2019 | 49 | 2019 |
| Prevention and treatment of FGFR inhibitor-associated toxicities A Mahipal, SH Tella, A Kommalapati, J Yu, R Kim Critical Reviews in Oncology/Hematology 155, 103091, 2020 | 48 | 2020 |
| Immunotherapy in hepatocellular carcinoma: is there a light at the end of the tunnel? A Mahipal, SH Tella, A Kommalapati, A Lim, R Kim Cancers 11 (8), 1078, 2019 | 44 | 2019 |
| Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma H Hashmi, AS Mirza, A Darwin, C Logothetis, F Garcia, A Kommalapati, ... Blood Advances 4 (17), 4086-4090, 2020 | 36 | 2020 |
| Natural killer/T-cell neoplasms: analysis of incidence, patient characteristics, and survival outcomes in the United States A Kommalapati, SH Tella, AK Ganti, JO Armitage Clinical Lymphoma Myeloma and Leukemia 18 (7), 475-479, 2018 | 30 | 2018 |
| Fluoroquinolone-associated suicide A Kommalapati, S Wallam, SH Tella, ZP Qureshi, CL Bennett European Journal of Internal Medicine 55, e21-e22, 2018 | 26 | 2018 |
| Regulatory and clinical experiences with biosimilar filgrastim in the US, the European Union, Japan, and Canada B Chen, S Nagai, JO Armitage, B Witherspoon, C Nabhan, AC Godwin, ... The oncologist 24 (4), 537-548, 2019 | 25 | 2019 |
| Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer G Goyal, A Kommalapati, AC Bartley, TM Gunderson, AA Adjei, RS Go Lung Cancer 122, 214-219, 2018 | 25 | 2018 |
| Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date SH Tella, A Mahipal, A Kommalapati, Z Jin OncoTargets and therapy, 10335-10342, 2019 | 22 | 2019 |
| A novel clinically based staging system for gallbladder cancer S Yadav, SH Tella, A Kommalapati, K Mara, K Prasai, MH Mady, ... Journal of the National Comprehensive Cancer Network 18 (2), 151-159, 2020 | 21 | 2020 |
| Thyrotoxic periodic paralysis: an underdiagnosed and under-recognized condition SH Tella, A Kommalapati Cureus 7 (10), 2015 | 21 | 2015 |
Sri Harsha Tella MD FACPMayo Clinic, Rochester, MN在 mayo.edu 的电子邮件经过验证
